Literature DB >> 3571052

Pharmacokinetics of vancomycin in serum and tissue of patients undergoing open-heart surgery.

F D Daschner, U Frank, A Kümmel, E Schmidt-Eisenlohr, V Schlosser, H Spillner, B Schuster, M Schindler.   

Abstract

Penetration of vancomycin into serum, heart valves, subcutaneous tissue and muscle was determined in 33 adult patients undergoing open-heart surgery. Each patient received 15 mg/kg vancomycin as a 30-min intravenous infusion preoperatively. Within 6 h vancomycin plasma concentrations declined from 28.9 to 4.2 mg/l. Vancomycin concentrations decreased in subcutaneous tissue slowly and varied in muscle between 1.2 and 3.2 mg/kg, in subcutaneous tissue between 1.3 and 4.4 mg/kg and in heart valves between 2.3 and 4.2 mg/kg. Vancomycin concentrations in heart valves are high enough to inhibit most oxacillin-resistant Staphylococcus aureus, and coagulase-negative staphylococci causing postoperative wound infections and endocarditis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3571052     DOI: 10.1093/jac/19.3.359

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  Penetration of vancomycin in uninfected sternal bone.

Authors:  L Massias; C Dubois; P de Lentdecker; O Brodaty; M Fischler; R Farinotti
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

2.  Concentrations of flucloxacillin in heart valves and subcutaneous and muscle tissues of patients undergoing open-heart surgery.

Authors:  U Frank; E Schmidt-Eisenlohr; V Schlosser; G Spillner; M Schindler; F D Daschner
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

3.  Penetration of teicoplanin into heart valves and subcutaneous and muscle tissues of patients undergoing open-heart surgery.

Authors:  U K Frank; E Schmidt-Eisenlohr; D Mlangeni; M Schindler; A Hoh; F Beyersdorf; F D Daschner
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

4.  Impact of administration of vancomycin or linezolid to critically ill patients with impaired renal function.

Authors:  O Rodriguez Colomo; F Álvarez Lerma; M I González Pérez; J-M Sirvent; M García Simón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-12       Impact factor: 3.267

5.  Concentrations of teicoplanin in serum and atrial appendages of patients undergoing cardiac surgery.

Authors:  M G Bergeron; R Saginur; D Desaulniers; S Trottier; W Goldstein; P Foucault; C Lessard
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

Review 6.  Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections.

Authors:  Christopher Giuliano; Christopher Giulano; Krystal K Haase; Ronald Hall
Journal:  Expert Rev Anti Infect Ther       Date:  2010-01       Impact factor: 5.091

Review 7.  Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin.

Authors:  Christian Eckmann; M Dryden
Journal:  Eur J Med Res       Date:  2010-11-30       Impact factor: 2.175

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.